Department of Biochemistry and Molecular Genetics, Faculty of Physical Therapy, Horus University - Egypt, New Damietta, Egypt.
School of Medicine, Tulane University, New Orleans, Louisiana, USA.
J Med Virol. 2021 May;93(5):2740-2768. doi: 10.1002/jmv.26836. Epub 2021 Feb 23.
A meta-analysis was performed to identify patients with coronavirus disease 2019 (COVID-19) presenting with gastrointestinal (GI) symptoms during the first and second pandemic waves and investigate their association with the disease outcomes. A systematic search in PubMed, Scopus, Web of Science, ScienceDirect, and EMBASE was performed up to July 25, 2020. The pooled prevalence of the GI presentations was estimated using the random-effects model. Pairwise comparison for the outcomes was performed according to the GI manifestations' presentation and the pandemic wave of infection. Data were reported as relative risk (RR), or odds ratio and 95% confidence interval. Of 125 articles with 25,252 patients, 20.3% presented with GI manifestations. Anorexia (19.9%), dysgeusia/ageusia (15.4%), diarrhea (13.2%), nausea (10.3%), and hematemesis (9.1%) were the most common. About 26.7% had confirmed positive fecal RNA, with persistent viral shedding for an average time of 19.2 days before being negative. Patients presenting with GI symptoms on admission showed a higher risk of complications, including acute respiratory distress syndrome (RR = 8.16), acute cardiac injury (RR = 5.36), and acute kidney injury (RR = 5.52), intensive care unit (ICU) admission (RR = 2.56), and mortality (RR = 2.01). Although not reach significant levels, subgroup-analysis revealed that affected cohorts in the first wave had a higher risk of being hospitalized, ventilated, ICU admitted, and expired. This meta-analysis suggests an association between GI symptoms in COVID-19 patients and unfavorable outcomes. The analysis also showed improved overall outcomes for COVID-19 patients during the second wave compared to the first wave of the outbreak.
一项荟萃分析旨在确定在第一波和第二波大流行期间出现胃肠道 (GI) 症状的 2019 年冠状病毒病 (COVID-19) 患者,并调查其与疾病结局的关系。截至 2020 年 7 月 25 日,在 PubMed、Scopus、Web of Science、ScienceDirect 和 EMBASE 中进行了系统检索。使用随机效应模型估计 GI 表现的汇总患病率。根据 GI 表现的出现和感染大流行波,对结局进行两两比较。数据以相对风险 (RR)、比值比和 95%置信区间报告。在 125 篇包含 25252 名患者的文章中,有 20.3%的患者出现 GI 表现。厌食症 (19.9%)、味觉丧失/味觉丧失 (15.4%)、腹泻 (13.2%)、恶心 (10.3%)和呕血 (9.1%)是最常见的。约 26.7%的患者粪便 RNA 检测呈阳性,平均在转为阴性前持续病毒脱落 19.2 天。入院时出现 GI 症状的患者发生并发症的风险较高,包括急性呼吸窘迫综合征 (RR=8.16)、急性心脏损伤 (RR=5.36)、急性肾损伤 (RR=5.52)、入住重症监护病房 (RR=2.56)和死亡率 (RR=2.01)。尽管未达到显著水平,但亚组分析显示,第一波受影响的队列住院、通气、入住 ICU 和死亡的风险较高。这项荟萃分析表明 COVID-19 患者的 GI 症状与不良结局之间存在关联。该分析还表明,与疫情第一波相比,第二波 COVID-19 患者的整体结局有所改善。